Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05889949 | Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma | unknown | — | 200 | Sun Yat-sen UniversityOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT05886465 | HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03567720 | Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | unknown | Phase 2 | 65 | OncoSec Medical IncorporatedINDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05393986 | Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors | unknown | Phase 1 | 63 | Peking UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05703750 | Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301) | unknown | — | 228 | Zhongda HospitalOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05704192 | CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302) | unknown | — | 373 | Zhongda HospitalOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05883176 | TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria(B-TACE) | unknown | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05879328 | The ImmunoXXL Study(ImmunoXXL) | unknown | — | 12 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05754788 | Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis | unknown | — | 40 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05302778 | Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer(HERMIONE-10) | unknown | — | 200 | University of Milano BicoccaOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05872412 | Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer | unknown | Phase 2 | 82 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05875558 | M-TACE Treatment for Unresectable Hepatocellular Carcinoma | unknown | N/A | 40 | Shanghai Zhongshan HospitalOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05876052 | HOPE to Reduce Tumour Recurrence After LT In Patients With HCC(POTERE) | unknown | N/A | 192 | University of BolognaOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05872841 | H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis | unknown | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05870813 | CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer(CLEAR-B) | unknown | — | 3,000 | Institut fuer FrauengesundheitOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05862181 | The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | unknown | — | 200 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05868252 | Molecular Analysis of the Sloane Project | unknown | — | 1,500 | King's College LondonOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05865730 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | unknown | Phase 2 | 122 | EverImmuneINDUSTRY | 2 | May 19, 2023 | clinicaltrials |
| NCT05866172 | HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC | unknown | Phase 3 | 264 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04967495 | TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT | unknown | N/A | 171 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05763992 | Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial(BREAKFAST-2) | unknown | Phase 2 | 145 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05859945 | Navigating the Clinical Trial Process for Hepatocellular Carcinoma | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 16, 2023 | clinicaltrials |
| NCT05831553 | TIP in Patients Affected by Metastatic TNBC(TIP) | unknown | — | 100 | Fondazione per la Medicina PersonalizzataOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05839886 | The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma(MEET) | unknown | — | 50 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT05843305 | A Study of BPI-452080 in Subjects With Solid Tumors | unknown | Phase 1 | 87 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT04111029 | Liquid Biopsy in Hepatocellular Carcinoma(HCCGenePanel) | unknown | — | 30 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05837065 | Prognostic Models for HCC Based on Tumor Micronecrosis | unknown | — | 765 | Zhejiang UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05134532 | Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC(HCC) | unknown | Phase 2 | 40 | CHA UniversityOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04164602 | The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly(NODES) | unknown | — | 2,522 | University of PecsOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04652440 | Ablation Combined With PD-1 in HCC: Phase II Study | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05285579 | Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer(ANGIOCOR) | unknown | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05036005 | Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)(NeoON) | unknown | Phase 4 | 108 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05816642 | Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma | unknown | N/A | 500 | RenJi HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05816863 | Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma | unknown | — | 32 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05814224 | Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA(MAGNETIC1) | unknown | N/A | 164 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05093920 | Role of DEB-TACE Versus c-TACE in Treatment of HCC | unknown | Early Phase 1 | 30 | Sohag UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05556200 | A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs | unknown | Phase 2 | 58 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05809869 | Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma | unknown | Phase 2 | 25 | The University of Hong KongOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05746728 | Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer | unknown | Phase 1 / Phase 2 | 45 | Huihua XiongOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05690958 | Public's Intended Uptake and Views on Organization of Esophageal Cancer Screening(ACCEPT-survey) | unknown | — | 2,088 | Radboud University Medical CenterOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05800236 | Characterisation of the Intratumoral Microbiome in Gastric Adenocarcinoma: to a Personalised Medicine(MICROGAS) | unknown | N/A | 20 | University Hospital, BordeauxOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05800561 | Prognostic Role of HVPG and ICG-R15 in the Short- and Medium-term Results of the Surgery of HCC on Cirrhosis(ProHype-ICG) | unknown | — | 208 | Federico II UniversityOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05796960 | European Multicenter Study on Surgical Management of Advanced Thyroid Cancer(ATCEU) | unknown | — | 3,917 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05798455 | Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Tabriz University of Medical SciencesOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT04601961 | Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients | unknown | N/A | 220 | The University of Hong KongOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT05790122 | Safety and Efficacy of Sutureless Zero Ischemia Laparoscopic Tumor Enucleation for T1 Stage Renal Carcinoma | unknown | — | 146 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT00492778 | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | unknown | Phase 2 | 165 | GOG FoundationNETWORK | 2 | Mar 29, 2023 | clinicaltrials |
| NCT03280667 | Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma(KEYPAD) | unknown | Phase 2 | 59 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Mar 29, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 7, 2023source: clinicaltrials